RE: AVCT RNS6 Aug 2020 08:20
9th June trading update, deal signed with mologic
New MTA covering additional Mologic COVID-19 tests
In addition, Omega announces it has widened its collaboration with Mologic by signing another Material Transfer Agreement ("MTA"), providing the Company with access to raw materials and know-how to manufacture the following additional Mologic COVID-19 tests:
· an ELISA antigen test that determines the concentration of COVID-19 (SARS-CoV-2) antigens in human blood, saliva or swab extract sample thereby identifying an individual with an active COVID-19 infection
· a lateral flow antigen test product that determines the concentration of COVID-19 (SARS-CoV-2) antigens in a human blood, saliva, or swab extract sample also used to identify an individual with an infection
· a lateral flow antibody test product that determines the concentration of human antibodies in a human blood sample specifically targeting the COVID-19 (SARS-CoV-2) antigens
Omega intends to CE-Mark the above additional tests under the MTA, after which both parties will work together to commercialise the tests under an expanded Supply Agreement arrangement. The MTA will enable Omega to broaden its growing portfolio of COVID-19 tests, using both its Scottish and English manufacturing sites more effectively, and will ensure it can meet the different needs of global healthcare systems that require both antibody tests (denoting previous infection) and antigen tests (denoting current infection) in a range of formats.